PDCD1 and melanoma: Our real-world analysis utilizing nation-wide data from multiple reference melanoma reference centers confirms that treatment with second-line anti-PD-1 therapy prolongs overall survival in selected patients with advanced/metastatic BRAF-mutated melanoma, including patients with initially poor performance status.